News
Cyrus Biotechnology Announces Selection of CYR212 as Clinical Candidate for Chronic IgG-driven Autoimmune Disease Including Myasthenia Gravis and Immune Thrombocytopenia (Business Wire)
January 13, 2025
Article can be read via the following link: Business Wire
Cyrus Biotechnology Spins out Levitate Bio, a Protein AI, Bioinformatics, and Rosetta Service Provider, to Bring Automated, Customized AI Solutions to Biopharma Drug Discovery
December 13, 2024
Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies (Business Wire)
December 11, 2024
Read article at the link below: Business Wire
Cyrus Biotechnology to Present its Protein Engineering Capability, Immunogenicity Risk Mitigation, and Best-in-Class IgG Protease Candidate at Hit ID Summit (Business Wire)
November 12, 2024
Cyrus CSO and co-founder Yifan Song performed a presentation at the Hit ID Summit in Boston, speaking on a few topics including Cyrus’ hybrid AI/screening platform in risk mitigation of protein therapeutics.
Cyrus Biotechnology Congratulate Co-Founder David Baker on 2024 Nobel Prize in Chemistry (Business Wire)
October 11, 2024
Cyrus co-founder and Computational Biologist David Baker was recently awarded as a 2024 Nobel Laureate in Chemistry. Congratulations to David on receiving such a prestigious honor. Here is the link to the article: Business Wire
Cyrus Biotechnology to Present Its Novel IgG-degrading IdeS Enzyme Development Candidates for Autoimmune Indications at PepTalk Conference in San Diego
January 17, 2024
Director of Discovery Dr. Erik Procko recently performed a presentation on Cyrus’ novel IgG-degrading IdeS enzyme development candidates at PepTalk Conference San Diego on January 16th. The article can be found via: Cyrus Website